<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566501</url>
  </required_header>
  <id_info>
    <org_study_id>E2020-G000-328</org_study_id>
    <secondary_id>2006-004890-93</secondary_id>
    <nct_id>NCT00566501</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease</brief_title>
  <official_title>Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of long-term administration&#xD;
      of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe&#xD;
      Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no&#xD;
      ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible&#xD;
      to enter the open-label extension study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2007</start_date>
  <completion_date type="Actual">April 1, 2010</completion_date>
  <primary_completion_date type="Actual">April 1, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology</measure>
    <time_frame>From the first dose of study drug up to 2 years 3 months</time_frame>
    <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to [&lt;=] 2,800/per millimeter (mm) or greater than or equal to [&gt;=] 16,000/mm; Neutrophils: &lt;=15 percent (%); Hemoglobin: Male (&lt;=11.5 gram per deciliter [g/dL]), Female (&lt;=9.5 g/dL); Hematocrit: Male (&lt;=37%), Female (&lt;=32%); Eosinophils: &gt;=10%; Platelet Count: &lt;=75,000/mm or &gt;=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry</measure>
    <time_frame>From the first dose of study drug up to 2 years 3 months</time_frame>
    <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(&lt;)130 milliequivalents per litre (mEq/L) or greater than(&gt;)150 mEq/L;Potassium:&lt;3 mEq/L or &gt;5.5 mEq/L; Calcium: &lt;8.4 milligram per deciliter (mg/dL) or &gt;1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:&gt;=3*upper limit of normal (ULN);Aspartate aminotransferase (AST):&gt;=3*ULN;Alanine aminotransferase(ALT):&gt;=3*ULN;Total Bilirubin:&gt;=2.0 mg/dL;Chloride:&lt;90 mEq/L or &gt;115 mEq/L;Creatinine:&gt;=2.0 mg/dL;Creatine phosphokinase:&gt;=3*ULN;Blood Urea Nitrogen (BUN):&gt;=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severe Impairment Battery (SIB) Total Score</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE) Total Score</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score</measure>
    <time_frame>At Baseline, Month 6 and Month 12</time_frame>
    <description>QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score</measure>
    <time_frame>At Baseline, Month 6 and Month 12</time_frame>
    <description>EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score</measure>
    <time_frame>At Baseline, Month 6 and Month 12</time_frame>
    <description>The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score</measure>
    <time_frame>At Baseline, Month 6 and Month 12</time_frame>
    <description>The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The subjective burden was the sum of the (total number with score*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Outcome Scale (TOS) Score</measure>
    <time_frame>At Months 6 and 12</time_frame>
    <description>TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goal Attainment Scaling (GAtS) Score Total Score</measure>
    <time_frame>At Months 6 and 12</time_frame>
    <description>GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' [no change]).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">915</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil SR 23 mg once daily orally.</description>
    <arm_group_label>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</arm_group_label>
    <arm_group_label>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Participants:&#xD;
&#xD;
          1. Written informed consent from the participant (if possible) or from the participant's&#xD;
             legal guardian or other representative at the time of the Baseline visit, prior to&#xD;
             beginning any assessments or activities.&#xD;
&#xD;
          2. Completion of study E2020-G000-326 (NCT00478205) without ongoing SAEs or history of&#xD;
             serious adverse drug reactions during study E2020-G000-326 (NCT00478205).&#xD;
&#xD;
          3. Participant must enroll in the present study within 3 days of completion of study&#xD;
             E2020-G000-326 (NCT00478205).&#xD;
&#xD;
          4. Health: physically healthy and ambulatory or ambulatory-aided (that is, walker or&#xD;
             cane); corrected vision and hearing sufficient for compliance with testing procedures.&#xD;
&#xD;
          5. Co-morbid medical conditions must be well-controlled as determined by the&#xD;
             investigator.&#xD;
&#xD;
          6. Participants undergoing treatment with selective serotonin reuptake inhibitors (SSRIs)&#xD;
             may be included, provided that doses are within the approved dose range as specified&#xD;
             in the Physician's Desk Reference or local equivalent&#xD;
&#xD;
          7. Concomitant Medications: Participants undergoing treatment with the following&#xD;
             medications may be enrolled in the study provided the following conditions are met:&#xD;
             chronic daily benzodiazepine use if doses are stable within an approved dose range;&#xD;
             bronchodilator medications for treatment of chronic obstructive pulmonary disease&#xD;
             (COPD) as long as drug is administered via metered dose inhaler within approved dose&#xD;
             range; memantine if taken at doses of 20 mg/day or less, provided that the dose is&#xD;
             stable.&#xD;
&#xD;
          8. The participants must have a relative/caregiver who supervises the regular taking of&#xD;
             the drug at the correct dose and is alert for possible side effects, unless the&#xD;
             participant's legal guardian takes on this task.&#xD;
&#xD;
        Inclusion Criteria for Caregivers. Written informed consent will be obtained from the&#xD;
        designated caregiver for participation in study assessments. The caregiver must be&#xD;
        sufficiently familiar with the participant (as determined by the investigator) to provide&#xD;
        accurate data. Specifically, the caregiver must have sufficient contact with the&#xD;
        participant to provide accurate reports of the participant's functioning, must be able to&#xD;
        observe for possible adverse events, and must be able to accompany the participant to all&#xD;
        visits. It is preferable that the caregiver be the same as in study E2020-G000-326&#xD;
        (NCT00478205). If no replacement caregiver is available who meets the caregiver&#xD;
        inclusion/exclusion criteria, the participant must be discontinued from the study.&#xD;
&#xD;
        Exclusion Criteria for Participants:&#xD;
&#xD;
          1. No caregiver available to meet the inclusion criteria for caregivers.&#xD;
&#xD;
          2. Participants with any active or clinically-significant conditions affecting&#xD;
             absorption, distribution, or metabolism of the study medication (example, inflammatory&#xD;
             bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose&#xD;
             intolerance).&#xD;
&#xD;
          3. Known plan for elective surgery during the study period that would require general&#xD;
             anesthesia and administration of neuromuscular blocking agents, such as&#xD;
             succinylcholine, to induce paralysis/muscle relaxation. Minor surgery, such as&#xD;
             colonoscopy or cataract surgery, will be permitted as long as it does not require the&#xD;
             use of these paralytic agents.&#xD;
&#xD;
          4. Participants who are unwilling or unable to fulfill the requirements of the study.&#xD;
&#xD;
          5. Use of any prohibited prior or concomitant medications.&#xD;
&#xD;
          6. Any condition that would make the participant, in the opinion of the investigator,&#xD;
             unsuitable for the study.&#xD;
&#xD;
          7. Participant taking concomitant antidepressant medication known to have significant&#xD;
             anticholinergic effects, such as tricyclic antidepressants prescribed at doses&#xD;
             recommended for the treatment of major depression.&#xD;
&#xD;
          8. Participants who cannot swallow or who have difficulty swallowing whole tablets.&#xD;
&#xD;
          9. Participants taking any alternative medication such as vitamins and/or herbal products&#xD;
             or alternative medical techniques such as acupuncture or acupressure specifically for&#xD;
             the treatment of Alzheimer's disease.&#xD;
&#xD;
        Exclusion Criteria for Caregivers.&#xD;
&#xD;
          1. Caregivers who are unwilling or unable to give informed consent or otherwise to&#xD;
             fulfill the requirements of the study.&#xD;
&#xD;
          2. Any condition that would make the caregiver, in the opinion of the investigator,&#xD;
             unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>91 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Yardley, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apex Research Institute</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>May 16, 2012</results_first_submitted>
  <results_first_submitted_qc>May 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate-to-severe</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 179 centers in Asia, Europe, North America, Oceania, South Africa, and South America during 14 December 2007 to 01 April 2010. This study E2020-G000-328 (NCT00566501) was a 12-month, open-label extension of study E2020-G000-326 (NCT00478205). Participants who had received donepezil 10 milligram (mg) immediate release (IR) or donepezil 23 mg sustained release (SR) during Study E2020-G000-326 (NCT00478205) were eligible for enrollment into this study.</recruitment_details>
      <pre_assignment_details>A total of 1084 participants completed the study E2020-G000-326 (NCT00478205), of which 915 participants were enrolled and signed informed consent form and out of them, 902 participants received treatment in this study E2020-G000-328 (NCT00566501).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
        <group group_id="P2">
          <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
                <participants group_id="P2" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Request of Investigator or Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
        <group group_id="B2">
          <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="570"/>
            <count group_id="B2" value="332"/>
            <count group_id="B3" value="902"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.1" spread="8.67"/>
                    <measurement group_id="B2" value="74.5" spread="8.44"/>
                    <measurement group_id="B3" value="74.3" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="373"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="575"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="429"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="674"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian/Pacific</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.</description>
        <time_frame>From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)</time_frame>
        <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.</description>
          <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology</title>
        <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to [&lt;=] 2,800/per millimeter (mm) or greater than or equal to [&gt;=] 16,000/mm; Neutrophils: &lt;=15 percent (%); Hemoglobin: Male (&lt;=11.5 gram per deciliter [g/dL]), Female (&lt;=9.5 g/dL); Hematocrit: Male (&lt;=37%), Female (&lt;=32%); Eosinophils: &gt;=10%; Platelet Count: &lt;=75,000/mm or &gt;=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.</description>
        <time_frame>From the first dose of study drug up to 2 years 3 months</time_frame>
        <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment. Here 'N' (overall number analyzed) are the participants who were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology</title>
          <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to [&lt;=] 2,800/per millimeter (mm) or greater than or equal to [&gt;=] 16,000/mm; Neutrophils: &lt;=15 percent (%); Hemoglobin: Male (&lt;=11.5 gram per deciliter [g/dL]), Female (&lt;=9.5 g/dL); Hematocrit: Male (&lt;=37%), Female (&lt;=32%); Eosinophils: &gt;=10%; Platelet Count: &lt;=75,000/mm or &gt;=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.</description>
          <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment. Here 'N' (overall number analyzed) are the participants who were evaluable for the outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry</title>
        <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(&lt;)130 milliequivalents per litre (mEq/L) or greater than(&gt;)150 mEq/L;Potassium:&lt;3 mEq/L or &gt;5.5 mEq/L; Calcium: &lt;8.4 milligram per deciliter (mg/dL) or &gt;1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:&gt;=3*upper limit of normal (ULN);Aspartate aminotransferase (AST):&gt;=3*ULN;Alanine aminotransferase(ALT):&gt;=3*ULN;Total Bilirubin:&gt;=2.0 mg/dL;Chloride:&lt;90 mEq/L or &gt;115 mEq/L;Creatinine:&gt;=2.0 mg/dL;Creatine phosphokinase:&gt;=3*ULN;Blood Urea Nitrogen (BUN):&gt;=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.</description>
        <time_frame>From the first dose of study drug up to 2 years 3 months</time_frame>
        <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment. Here 'N' (overall number analyzed) are the participants who were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry</title>
          <description>A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(&lt;)130 milliequivalents per litre (mEq/L) or greater than(&gt;)150 mEq/L;Potassium:&lt;3 mEq/L or &gt;5.5 mEq/L; Calcium: &lt;8.4 milligram per deciliter (mg/dL) or &gt;1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:&gt;=3*upper limit of normal (ULN);Aspartate aminotransferase (AST):&gt;=3*ULN;Alanine aminotransferase(ALT):&gt;=3*ULN;Total Bilirubin:&gt;=2.0 mg/dL;Chloride:&lt;90 mEq/L or &gt;115 mEq/L;Creatinine:&gt;=2.0 mg/dL;Creatine phosphokinase:&gt;=3*ULN;Blood Urea Nitrogen (BUN):&gt;=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.</description>
          <population>The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment. Here 'N' (overall number analyzed) are the participants who were evaluable for the outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severe Impairment Battery (SIB) Total Score</title>
        <description>The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>The Intent-to-treat (ITT) population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severe Impairment Battery (SIB) Total Score</title>
          <description>The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.</description>
          <population>The Intent-to-treat (ITT) population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="546"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="19.05"/>
                    <measurement group_id="O2" value="77.2" spread="19.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="546"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="7.11"/>
                    <measurement group_id="O2" value="-0.9" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="9.52"/>
                    <measurement group_id="O2" value="-2.8" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="462"/>
                    <count group_id="O2" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="11.19"/>
                    <measurement group_id="O2" value="-5.2" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="12.99"/>
                    <measurement group_id="O2" value="-6.7" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE) Total Score</title>
        <description>MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE) Total Score</title>
          <description>MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="549"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="5.81"/>
                    <measurement group_id="O2" value="13.8" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.27"/>
                    <measurement group_id="O2" value="-0.5" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="493"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.70"/>
                    <measurement group_id="O2" value="-1.2" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.95"/>
                    <measurement group_id="O2" value="-1.7" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.08"/>
                    <measurement group_id="O2" value="-2.1" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score</title>
        <description>ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score</title>
          <description>ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="556"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="11.26"/>
                    <measurement group_id="O2" value="34.3" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="555"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="5.30"/>
                    <measurement group_id="O2" value="-1.8" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="500"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="6.13"/>
                    <measurement group_id="O2" value="-3.7" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="6.91"/>
                    <measurement group_id="O2" value="-4.8" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="7.62"/>
                    <measurement group_id="O2" value="-6.8" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score</title>
        <description>QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.</description>
        <time_frame>At Baseline, Month 6 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score</title>
          <description>QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="527"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Caregiver; Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="527"/>
                    <count group_id="O2" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="6.37"/>
                    <measurement group_id="O2" value="30.8" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caregiver; Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="525"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="5.17"/>
                    <measurement group_id="O2" value="-1.4" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caregiver; Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="5.60"/>
                    <measurement group_id="O2" value="-1.8" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant; Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="465"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="6.65"/>
                    <measurement group_id="O2" value="34.5" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant; Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="453"/>
                    <count group_id="O2" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.10"/>
                    <measurement group_id="O2" value="-0.1" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant; Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.02"/>
                    <measurement group_id="O2" value="-0.2" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score</title>
        <description>EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).</description>
        <time_frame>At Baseline, Month 6 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score</title>
          <description>EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="531"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.17"/>
                    <measurement group_id="O2" value="0.77" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.15"/>
                    <measurement group_id="O2" value="-0.04" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.18"/>
                    <measurement group_id="O2" value="-0.06" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score</title>
        <description>The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).</description>
        <time_frame>At Baseline, Month 6 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score</title>
          <description>The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="520"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="4.36"/>
                    <measurement group_id="O2" value="9.8" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="516"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.76"/>
                    <measurement group_id="O2" value="1.0" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="430"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.94"/>
                    <measurement group_id="O2" value="1.5" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score</title>
        <description>The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The subjective burden was the sum of the (total number with score*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).</description>
        <time_frame>At Baseline, Month 6 and Month 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score</title>
          <description>The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from &quot;0&quot; (no occurrence) to &quot;4&quot; (occurrence with severe distress). The subjective burden was the sum of the (total number with score*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="520"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="10.98"/>
                    <measurement group_id="O2" value="18.5" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="516"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="10.03"/>
                    <measurement group_id="O2" value="3.0" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="430"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="10.30"/>
                    <measurement group_id="O2" value="4.3" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Outcome Scale (TOS) Score</title>
        <description>TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).</description>
        <time_frame>At Months 6 and 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Outcome Scale (TOS) Score</title>
          <description>TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>1=Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2=Moderately improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3=Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4=About the same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5=Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6=Moderately worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7=Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="440"/>
                    <count group_id="O2" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>1=Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2=Moderately improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3=Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4=About the same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5=Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6=Moderately worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7=Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Goal Attainment Scaling (GAtS) Score Total Score</title>
        <description>GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' [no change]).</description>
        <time_frame>At Months 6 and 12</time_frame>
        <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
          <group group_id="O2">
            <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
            <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
          </group>
        </group_list>
        <measure>
          <title>Goal Attainment Scaling (GAtS) Score Total Score</title>
          <description>GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' [no change]).</description>
          <population>The ITT population included all safety participants who have at least one post-baseline efficacy measurement. Here 'N' (overall number of participants analyzed) included all participants who were evaluable for this outcome measure and 'n' (number analyzed) included all participants who were evaluable at specified timepoints for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Caregivers; At Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="9.63"/>
                    <measurement group_id="O2" value="-3.2" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caregivers At Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="11.10"/>
                    <measurement group_id="O2" value="-5.9" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants; At Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="7.34"/>
                    <measurement group_id="O2" value="-0.8" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants; At Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.89"/>
                    <measurement group_id="O2" value="-0.6" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug up to 2 years 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
        <group group_id="E2">
          <title>Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)</title>
          <description>Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardio-rspiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Meningocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Peritonillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimers type</sub_title>
                <counts group_id="E1" events="570" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ischemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Poriomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="415" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Information</name_or_title>
      <organization>Eisai, Inc.</organization>
      <phone>+1-888-274-2378</phone>
      <email>esi_medinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

